COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) — COLLIGO-HCM

Hypertrophic Cardiomyopathy (HCM) Clinical Trial

Official title:
mavaCamten ObservationaL evIdence Global cOnsortium in HCM (COLLIGO-HCM)

Status Active, not recruiting

Clinical Trial Summary

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

Clinical Trial Description

The mavaCamten ObservationaL evIdence Global cOnsortium in hypertrophic cardiomyopathy (COLLIGO-HCM) is a global observational research initiative aiming to describe the real-world outcomes of treatments for obstructive hypertrophic cardiomyopathy (HCM), including mavacamten. This retrospective study uses data from existing medical records and electronic registries from HCM centers around the world. ;

Study Design

Related Conditions & MeSH terms

Cardiomyopathies
Cardiomyopathy, Hypertrophic
Hypertrophic Cardiomyopathy (HCM)
Hypertrophy

Clinical Trial Details

NCT number	NCT06372457
Study type	Observational
Source	Bristol-Myers Squibb
Contact
Status	Active, not recruiting
Phase
Start date	December 1, 2023
Completion date	June 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00753233` - Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy	N/A
Completed	`NCT01623245` - Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Completed	`NCT04219826` - Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM	Phase 2
Enrolling by invitation	`NCT04189822` - Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
Enrolling by invitation	`NCT02413450` - Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias